难治性高血压新药取得突破！阿斯利康(AZN.US)潜在重磅疗法Baxdrostat临床试验告捷

Group 1 - AstraZeneca announced that its experimental hypertension drug Baxdrostat effectively lowers blood pressure in patients with resistant or poorly controlled hypertension, enhancing the drug's development prospects [1] - In a late-stage clinical trial, patients taking Baxdrostat showed significant and clinically meaningful reductions in systolic blood pressure after 12 weeks compared to those on a placebo [1] - Following the announcement, AstraZeneca's stock rose by 2.1% in early trading on the London Stock Exchange, although the stock price has remained flat year-to-date [1] Group 2 - Baxdrostat was acquired by AstraZeneca in 2023 as part of its $18 billion purchase of CinCor Pharma Inc., with the company projecting annual sales could exceed $5 billion [1] - Barclays Bank estimates that the annual sales for Baxdrostat as a monotherapy could be around $2 billion [1] - Approximately 50% of hypertension patients in the U.S. receiving multiple treatments still cannot effectively control their blood pressure, indicating a significant market opportunity for Baxdrostat [1] Group 3 - Under CEO Pascal Soriot's leadership, AstraZeneca has become a giant in the oncology drug sector, while also having a rich pipeline in other disease areas, particularly cardiovascular, renal, and metabolic diseases, which are seen as core growth areas for the future [2]